What is hGH Frag 176-191?

hGH Fragment 176-191 is a synthetic peptide fragment constructed from the amino acid sequence 176-191 of the C-terminal portion of human growth hormone (hGH). This molecule was developed to separately investigate the lipolytic properties attributed to certain segments of GH, without reproducing the full physiological profile of growth hormone. In scientific literature, hGH Frag 176-191 has been considered a model compound for studies on lipolysis, lipid metabolism, and energy balance.

Unlike full-length hGH, hGH Frag 176-191 is not associated with a significant increase in IGF-1 and does not demonstrate the typical growth effects on tissues and organs. Instead, in experimental models, the peptide has been associated with stimulating fatty acid breakdown and limiting lipogenesis processes. Therefore, it is used as a research tool in studying mechanisms related to fat metabolism and metabolic regulation.

Observations on HGH Frag 176-191

In published scientific literature, HGH Frag 176-191 has been investigated in relation to the following:

• Stimulation of lipolysis – aids in the breakdown of fatty acids in adipocyte models

• Inhibition of lipogenesis – associated with limiting the accumulation of new fat deposits

• Regulation of body weight – considered a potential model for metabolic modulation

• Maintenance of lean muscle mass – without the pronounced anabolic profile characteristic of full GH

• Reduction of visceral adipose tissue – observed in models related to obesity

• Insulin sensitivity – effects described in some preclinical studies

Administration and Dosage

In scientific publications and experimental protocols, amounts in the range of 250-500 μg daily are found, typically administered subcutaneously under controlled research conditions and often divided into 1-2 applications. The peptide is most often considered in short-term research models focused on lipolytic mechanisms. hGH Frag 176-191 is among the more hydrophobic peptides, which may limit its solubility and typically requires using the entire solution.

For 5 mg + 3 ml bacteriostatic water:

Concentration = 1.67 mg/ml → 0.06 ml = 100 μg

Example values:

0.06 ml = 100 μg

0.12 ml = 200 μg

0.18 ml = 300 μg

0.24 ml = 400 μg

Scientific Data

HGH Frag 176-191 has been primarily the subject of preclinical studies, as well as limited clinical observations. The main scientific data described include:

• Increased lipolytic activity in adipocyte cultures and experimental models

• Reduction of total and visceral adipose tissue without significant changes in IGF-1 levels

• Lack of a distinct effect on glucose homeostasis at low experimental quantities

• Absence of observed influence on organ and tissue growth

• Improvements in lipid metabolism and energy efficiency in some preclinical models

Application in Sports and Research Settings

HGH Fragment 176-191 is listed by WADA as a controlled substance and is not permitted for use by professional athletes. In laboratory and academic contexts, the peptide is used to study lipolytic processes, energy metabolism, and models related to metabolic syndrome, obesity, and insulin resistance.

• Model for studying mechanisms related to fat tissue reduction

• Studies on insulin sensitivity, lipid metabolism, and energy balance

• Investigation of potential interaction with other peptides involved in metabolic regulation

Possible Side Effects

In the available scientific literature, HGH Frag 176-191 is generally described as well-tolerated within research settings. Observed reactions are primarily mild and transient:

• Local redness or discomfort at the experimental application site

• Mild fatigue or drowsiness

• Headache at higher experimental quantities

No serious adverse reactions at research quantities are reported in the published data. The described effects are primarily dose-dependent, temporary, and dependent on the conditions of the specific model.

The information is based on scientific literature and is for educational purposes. It does not constitute medical advice and is not intended for diagnosis, treatment, prevention, or use in humans or animals.